Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CYAD-211 in relapsed/refractory multiple myeloma
NCT04613557Phase 1Active, not recruiting
- Sponsor
- Celyad Oncology
- Start
- Nov 2020
- Primary completion
- Dec 2022
- Modality
- CAR-T Cells, RNA Therapeutics
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of CYAD-211 in multiple myeloma (MM), sponsored by Celyad Oncology. Primary endpoint: Occurrence of Dose Limiting Toxicities at 36 days. Started Nov 2020; status: active, not recruiting.
02
Drugs
CYAD-211
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT04613557.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04613557.